# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## FORM 8-K

## CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): October 30, 2023

# The Vita Coco Company, Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation) 001-40950 (Commission

(Commission File Number) 11-3713156 (I.R.S. Employer Identification No.)

250 Park Avenue South Seventh Floor New York, New York 10003 (Address of principal executive offices) (Zip Code)

(Registrant's telephone number, include area code) (212) 206-0763

 $$\mathbf{N}/\mathbf{A}$$  (Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Dere-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Dere-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

	Trading	Name of each exchange
Title of each class	Symbols	on which registered
Common Stock, \$0.01 par value per share	COCO	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company X

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

#### Item 2.02 Results of Operations and Financial Condition.

On October 31, 2023, The Vita Coco Company, Inc. (the "Company") issued a press release announcing financial results for the three and nine months ended September 30, 2023 and other matters described in the press release. A copy of the Company's press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.

#### Item 8.01 Other Events.

On October 30, 2023, the Company's Board of Directors approved a share repurchase program (the "Program") authorizing the Company to repurchase up to \$40 million of the Company's common stock, par value \$0.01 per share ("Common Stock").

Shares of Common Stock may be repurchased under the Program from time to time through open market purchases, block trades, private transactions or accelerated or other structured share repurchase programs. To the extent not retired, shares of Common Stock repurchased under the Program will be placed in the Company's treasury shares.

The extent to which the Company repurchases shares of Common Stock, and the timing of such repurchases, will depend upon a variety of factors, including market conditions, regulatory requirements and other corporate considerations, as determined by the Company. The Program may be suspended or discontinued at any time.

#### Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press release, dated October 31, 2023.

104 Cover Page Interactive Data File (embedded with Inline XBRL document)

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

THE VITA COCO COMPANY, INC.

Date: October 31, 2023

By: /s/ Corey Baker

Name: Corey Baker Title: Chief Financial Officer

#### THE VITA COCO COMPANY REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS

Third Quarter Net Sales Increased 11% to \$138MM; Year-To-Date Net Sales Grew 15%

Third Quarter Gross Margin of 41%, an Improvement of Over 1,400 Basis Points Over 2022

Company Raises Full Year Net Sales and Adjusted EBITDA<sup>(1)</sup> Guidance

Company Announces \$40MM Share Repurchase Program

NEW YORK, October 31, 2023(GLOBE NEWSWIRE) - - The Vita Coco Company, Inc. (NASDAQ: COCO) ("Vita Coco" or the "Company"), a leading high-growth platform of better-for-you beverage brands, today announced financial results for the third quarter ended September 30, 2023.

#### Third Quarter 2023 Highlights Compared to Prior-Year Period

- Net sales grew by 11% to \$138 million driven by strong 8% net sales growth and 5% volume growth of *Vita Coco* Coconut Water which continues to be the largest contributor to growth on a consolidated basis.
- Gross profit was \$56 million, or 41% of net sales, an increase of \$24 million as compared to 26% of net sales in the prior-year period with the improvement driven by lower year-over-year transportation costs, net sales growth and higher *Vita Coco* Coconut Water pricing.
- Net income was \$15 million, or \$0.26 per diluted share, compared to \$7 million, or \$0.13 per diluted share. Net income benefited from strong net
  sales growth and gross margin improvement resulting primarily from decreased transportation costs, partially offset by increased investments in
  sales, general and administrative ("SG&A") and a mark-to-market adjustment in foreign currency hedges.
- Non-GAAP Adjusted EBITDA<sup>1</sup> was \$27 million, compared to \$12 million in the prior-year period, up \$15 million due to improvements in gross
  profit partially offset by increased SG&A spending.

#### 2023 Year-To-Date Highlights Compared to Prior-Year Period

- Net sales grew 15% to \$387 million driven by strong 16% net sales growth and 13% volume growth of *Vita Coco* Coconut Water which continues to be the largest contributor to growth on a consolidated basis.
- Gross profit was \$141 million, or 36% of net sales, an increase of \$60 million as compared to 24% of net sales in the prior-year period, with the increase driven primarily by lower year-over-year transportation costs, net sales growth and increased *Vita Coco* Coconut Water pricing.
- Net income was \$40 million, or \$0.68 per diluted share, compared to \$11 million, or \$0.19 per diluted share, in the prior-year period with the increase driven by strong net sales growth and gross margin improvement resulting primarily from decreased transportation costs, partially offset by increased investments in SG&A, a mark-to-market adjustment in foreign currency hedges, and increased tax expense.
- Non-GAAP Adjusted EBITDA<sup>1</sup> was \$60 million, compared to \$16 million in the prior-year period due to improvements in gross profit partially offset by increased SG&A spending.

Michael Kirban, the Company's Co-Founder and Executive Chairman, stated, "I am very proud of our team and its continued strong performance this year. We have delivered another strong quarter and we believe that our focus on expanding consumption occasions for coconut water is contributing to strong volume performance for our flagship *Vita Coco* Coconut Water brand. The organization's ability to drive incredible volume growth while continuing to improve profitability and cash generation at the same time is something that every member of the team should be proud of." Martin Roper, the Company's Chief Executive Officer, said, "We are extremely pleased with this quarter's results with 11% net sales growth and Adjusted EBITDA<sup>1</sup> of \$27 million. Gross margins for the quarter exceeded our expectations due to better than expected price realization across our business, and the stabilization of our transportation costs. We are raising our full year net sales and Adjusted EBITDA<sup>1</sup> guidance based on the strong third quarter and an updated view on fourth quarter shipments and product mix. We remain focused on investments to support the health of our brands and drive sustainable long term growth."

#### Third Quarter 2023 Consolidated Results

Net sales increased \$14 million, or 11%, to \$138 million for the third quarter ended September 30, 2023, compared to \$124 million for the third quarter ended September 30, 2022. The increase in net sales was driven by increased case equivalent ("CE") volumes coupled with some benefits from net pricing actions on branded products partially offset by price/mix of private label products.

Improved gross margins and gross profit versus prior-year resulted from the reduction of transportation costs coupled with increased branded pricing and increased sales volumes. Gross profit was \$56 million for the third quarter of 2023, which was an increase of \$24 million compared to the same prior-year period. Gross margin of 41% in the third quarter represented a sequential improvement of over 400 basis points from the second quarter of 2023, and an increase of greater than 1400 basis points from 26% in the same prior-year period.

SG&A expenses in the third quarter of 2023 were \$33 million, compared to \$24 million in the prior-year period. The increase was largely due to investments in marketing expenses and higher personnel related expenses.

Net income was \$15 million, or \$0.26 per diluted share, for the third quarter of 2023, compared to \$7 million, or \$0.13 per diluted share in the third quarter of 2022. Net income benefited from strong gross profit, partially offset by increased SG&A investments, a non-cash mark-to-market loss in the fair value of foreign currency hedges of \$4 million versus a gain of \$1 million last year and by an increase in tax expense of \$2 million.

Non- GAAP Adjusted EBITDA<sup>1</sup> for the third quarter of 2023 was \$27 million, compared to \$12 million in the prior-year period. The increase in Adjusted EBITDA<sup>1</sup> was primarily driven by strong net sales growth and gross margin improvement resulting primarily from decreased transportation costs and improved branded pricing, partially offset by increased investments in SG&A.

#### **Balance Sheet**

As of September 30, 2023, the Company had cash and cash equivalents of \$95 million and no debt under its revolving credit facility, compared to \$20 million and no debt, as of December 31, 2022. The increase in net cash was driven by improved net income performance and reductions in working capital. On September 30, 2023, there were 56,756,005 shares of common stock outstanding.

On October 30, 2023, the Company's Board of Directors approved a share repurchase program ("Program") authorizing the Company to repurchase up to \$40 million of the Company's common stock. Shares of common stock may be repurchased under the Program from time to time through open market purchases, block trades, private transactions or accelerated or other structured share repurchase programs.

#### Fiscal Year 2023 Full Year Outlook

The Company is updating its previously communicated full year 2023 guidance:

- Expect net sales growth of approximately 13-15% compared to fiscal year 2022 [previously 10-12%], based on mid teens *Vita Coco* Coconut Water growth and strength in private label resulting from expanded distribution with new and existing customers, plus our revised expectation of retaining the majority of a key customer's private label coconut water business.
- Full year gross margins in the range of 35% to 37% [no change] benefiting from improved transportation costs and branded pricing, partially
  offset by expected private label price/mix impacts.
- Forecast Adjusted EBITDA<sup>2</sup> in the range of \$64-67 million [previously \$56-60 million] reflecting full year net sales growth and gross margin
  improvement offset by increased investment in SG&A to support the long term growth of the company.

Management to provide an update on its private label business and outlook during the earnings conference call later today.

#### Footnotes:

(1) Adjusted EBITDA represents earnings before interest, taxes, depreciation, and amortization, as adjusted for certain items as set forth in the reconciliation table of U.S. GAAP to non-GAAP information and is a measure calculated and presented on the basis of methodologies other than in accordance with GAAP. Please refer to the Use of Non-GAAP Financial Information herein for further discussion and reconciliation of this measure to GAAP measures.

(2) GAAP Net Income 2023 outlook is not provided due to the inherent difficulty in quantifying certain amounts due to a variety of factors, including the unpredictability in the movement in foreign currency rates, as well as future charges or reversals outside of the normal course of business.

#### **Conference Call and Webcast Details**

The Vita Coco Company will host a conference call and webcast at 8:30 a.m. ET today to discuss these results. To participate in the live earnings call and question and answer session, please register at https://register.vevent.com/register/BI1c04615dffc74402a2b94fb894e2f2b6 and dial-in information will be provided directly to you. A slide presentation to support the webcast, and the live audio webcast will be accessible in the "Events" section of the Company's Investor Relations website at https://investors.thevitacococompany.com. An archived replay of the webcast will be available shortly after the live event has concluded.

#### About The Vita Coco Company

The Vita Coco Company was co-founded in 2004 by Chairman Michael Kirban and Ira Liran. Pioneers in the functional beverage category, The Vita Coco Company's brands include the leading coconut water, Vita Coco; clean energy drink, Runa; sustainable enhanced water, Ever & Ever; and protein-infused water, PWR LIFT. With its ability to harness the power of people and plants, and balance purpose and profit, The Vita Coco Company has created a modern beverage platform built for current and future generations.

The company is a Public Benefit Corporation in Delaware and is a Certified B Corporation.™

**Contacts** Investor Relations:

ICR, Inc. investors@thevitacococompany.com

#### **Non-GAAP Financial Measures**

In addition to disclosing results determined in accordance with U.S. GAAP, the Company also discloses certain non-GAAP results of operations, including, but not limited to, Adjusted EBITDA, that include certain adjustments or exclude certain charges and gains that are described in the reconciliation table of U.S. GAAP to non-GAAP information provided at the end of this release. These non-GAAP measures are a key metric used by management and our board of directors to assess our financial performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance and because we believe it is useful for investors to see the measures that management uses to evaluate the Company. In addition, we believe the presentation of these measures is useful to investors for period-to-period comparisons of results as the items described below in the reconciliation tables do not reflect ongoing operating performance.

These measures are not in accordance with, or an alternative to, U.S. GAAP, and may be different from non-GAAP measures used by other companies. In addition, other companies, including companies in our industry, may calculate such measures differently, which reduces its usefulness as a comparative measure. Investors should not rely on any single financial measure when evaluating our business. This information should be considered as supplemental in nature and is not meant as a substitute for our operating results in accordance with U.S. GAAP. We recommend investors review the U.S. GAAP financial measures included in this earnings release. When viewed in conjunction with our U.S. GAAP results

and the accompanying reconciliations, we believe these non-GAAP measures provide greater transparency and a more complete understanding of factors affecting our business than U.S. GAAP measures alone.

#### **Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including but not limited to, statements regarding our future financial and operating performance, including our GAAP and non-GAAP guidance, our strategy, projected costs, prospects, expectations, plans, objectives of management, supply chain predictions, customer and supplier relationships and expected net sales and category share growth.

The forward-looking statements in this release are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements involve a number of risks, uncertainties or other factors beyond the Company's control. These factors include, but are not limited to, those discussed under the caption "Risk Factors" in our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and our other filings with the U.S. Securities and Exchange Commission ("SEC") as such factors may be updated from time to time and which are accessible on the SEC's website at www.sec.gov and the Investor Relations page of our website at https://investors.thevitacococompany.com. Any forward-looking statements contained in this press release speak only as of the date hereof and accordingly undue reliance should not be placed on such statements. We disclaim any obligation or undertaking to update or revise any forward-looking statements contained in this press release, whether as a result of new information, future events or otherwise, other than to the extent required by applicable law.

#### Website Disclosure

We intend to use our websites, vitacoco.com and investors.thevitacococompany.com, as a means for disclosing material non-public information and for complying with the SEC's Regulation FD and other disclosure obligations.

## THE VITA COCO COMPANY, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Amounts in thousands, except share data)

	Se	ptember 30, 2023	]	December 31, 2022
Assets				
Current assets:				
Cash and cash equivalents	\$	94,885	\$	19,629
Accounts receivable, net of allowance of \$2,849 at September 30, 2023, and \$2,898 at December 31, 2022		79,577		43,350
Inventory		50,380		84,115
Supplier advances		1,525		1,534
Derivative assets		3,147		3,606
Asset held for sale		_		503
Prepaid expenses and other current assets		17,794		22,181
Total current assets		247,308		174,918
Property and equipment, net		2,225		2,076
Goodwill		7,791		7,791
Supplier advances		3,462		4,360
Deferred tax assets, net		4,251		4,256
Right-of-use assets, net		1,718		2,679
Other assets		1,724		1,677
Total assets	\$	268,479	\$	197,757
Liabilities and Stockholders' Equity				
Current liabilities:				
Accounts payable		21,411		15,910
Accrued expenses and other current liabilities		51,242		38,342
Notes payable, current		15		23
Derivative liabilities		1,371		71
Total current liabilities		74,039		54,346
Notes payable, long-term		15		25
Other long-term liabilities		1,822		2,293
Total liabilities		75,876		56,664
Stockholders' equity:				
Common stock, \$0.01 par value; 500,000,000 shares authorized; 62,962,205 and 62,225,250 shares issued at September 30, 2023 and December 31, 2022, respectively; 56,756,005 and 56,019,050 Shares Outstanding at September 30, 2023 and December 31, 2022,				
respectively.		629		622
Additional paid-in capital		158,244		145,210
Retained earnings		93,969		55,183
Accumulated other comprehensive loss		(1,311)		(994)
Treasury stock, 6,206,200 shares at cost as of September 30, 2023, and December 31, 2022.		(58,928)		(58,928)
Total stockholders' equity attributable to The Vita Coco Company, Inc.		192,603		141,093
Total liabilities and stockholders' equity	\$	268,479	\$	197,757

## THE VITA COCO COMPANY, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (Amounts in thousands, except for share and per share data)

	-	Three Months Ended September 30,			Nine Months Ended September 30,			
		2023		2022		2023		2022
Net sales	\$	138,064	\$	124,043	\$	387,468	\$	335,796
Cost of goods sold		81,893		91,467		246,542		254,868
Gross profit		56,171	_	32,576		140,926		80,928
Operating expenses								
Selling, general and administrative		32,649		23,960		89,855		73,018
Income (Loss) from operations		23,522		8,616		51,071		7,910
Other income (expense)								
Unrealized gain/(loss) on derivative instruments		(3,959)		952		(1,758)		6,416
Foreign currency gain/(loss)		(1,211)		(364)		(430)		(508)
Interest income		824		20		1,105		30
Interest expense		(1)		(130)		(31)		(213)
Total other income (expense)		(4,347)		478		(1,114)		5,725
Income before income taxes		19,175		9,094		49,957		13,635
Income tax expense		(4,011)		(1,836)		(10,101)		(3,011)
Net income	\$	15,164	\$	7,258	\$	39,856	\$	10,624
Net income per common share								
Basic	\$	0.27	\$	0.13	\$	0.71	\$	0.19
Diluted	\$	0.26	\$	0.13	\$	0.68	\$	0.19
Weighted-average number of common shares outstanding					_			
Basic		56,493,757	_	55,785,622	_	56,290,195		55,658,946
Diluted		59,271,757	_	56,579,912		58,494,045		56,029,069
			_		_			

### THE VITA COCO COMPANY, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (Amounts in thousands)

Net income\$39,856\$10.624Adjustments required to reconcile net income to cash flows from operating activities:<		Nine Months Ended September 30,			
Net income\$39,856\$10.624Adjustments required to reconcile net income to cash flows from operating activities:<			2023		2022
Adjustments required to reconcile net income to cash flows from operating activities:Depreciation and amortization5031,442(Gain/)loss on disposal of equipment19—Bad debt expense255348Unrealized (gain/)loss on derivative instruments1,758(6,6416)Stock-based compensation7,1265,657Impairment loss on long-lived asset363619Noncash lease expense966963Changes in operating assets and liabilities:33,815(20,696)Inventory33,815(255)Prepaid expenses, net supplier advances, and other assets5,215(4,433)Accounts payable, acrued expenses, and other liabilities17,361(6,034)Net cash provided by (used in) operating activities70,003(18,181)Cash flows from investing activities(533)(907)Cash paid for property and equipment5—Vet cash used in investing activities(533)(907)Cash paid for property and equipment5—Proceeds from sale of property and equipment5—Proceeds from exercise of stock awards5,9152,675Borrowings on credit facility—22,000Reayments of borrowings on credit facility—(22,000Cash received (paid) on notes payable5,897(22,500)Cash received (paid) on notes payable5,897(22,500)Cash received form exercise of stock awards5,897(22,500)Cash received (paid) on notes payable(18) </th <th>Cash flows from operating activities:</th> <th></th> <th></th> <th></th> <th></th>	Cash flows from operating activities:				
Depreciation and amortization         503         1,442           (Gain)/loss on disposal of equipment         19         —           Bad debt expense         255         348           Unrealized (gain)/loss on derivative instruments         1,758         (6,416)           Stock-based compensation         7,126         5,657           Impairment loss on long-lived asset         363         619           Noncash lease expense         363         6255           Accounts receivable         (37,234)         (20,696)           Inventory         33,815         (255)           Prepaid expenses, net supplier advances, and other assets         5,215         (4,433)           Accounts	Net income	\$	39,856	\$	10,624
(Gain)/loss on disposal of equipment19Bad debt expense255348Unrealized (gain)/loss on derivative instruments1,758(6,416)Stock-based compensation7,1265,657Impairment loss on long-lived asset3636,619Noncash lease expense966963Changes in operating assets and liabilities:966963Changes in operating assets and liabilities:3,815(20,696)Inventory33,815(20,695)Prepaid expenses, net supplier advances, and other assets5,215(4,433)Accounts payable, accrued expenses, and other liabilities17,361(6,034)Net cash provided by (used in) operating activities70,003(18,181)Cash plaid for property and equipment5Cash paid for property and equipment5Net cash used in investing activities(528)(907)Proceeds from sale of property and equipment5Proceeds from sale of property and equipment5Proceeds from exercise of stock awards5,9152,675Borrowings on credit facility(22,000)Repayments of borrowings on credit facility(22,000)Cash received (paid) on ones payable(18)(222)Net cash provided by (used in) financing activities5,997(21,550)Cash received (paid) on ones payable(212)(544)Net cash provided by (used in) financing activities5,997(21,550)Cash received (paid) on ones pay	Adjustments required to reconcile net income to cash flows from operating activities:				
Bad debt expense255348Unrealized (gain)/loss on derivative instruments1,758(6,416)Stock-based compensation7,1265,657Impairment loss on long-lived asset363619Noncash lease expense966963Changes in operating assets and liabilities:33,815(20,696)Inventory(37,234)(20,696)Inventory33,815(255)Prepaid expenses, net supplier advances, and other assets5,215(4,433)Accounts payable, accrued expenses, and other liabilities70,003(18,181)Cash provided by (used in) operating activities70,003(18,181)Cash paid for property and equipment5Net cash used in investing activities(538)(907)Proceeds from sale of property and equipment5Proceeds from exercise of stock awards5,9152,675Borrowings on credit facility22,000Repayments of borrowings on credit facility(12,500)Cash received (paid) on notes payable(18)(22)Net cash provided by (used in) financing activities5,89712,153Effects of exchange rate changes on cash and cash equivalents75,584(7,479)Cash and cash equivalents75,584(7,479)Cash and cash equivalents75,584(7,479)	Depreciation and amortization		503		1,442
Unrealized (gain)/loss on derivative instruments1,758(6,416)Stock-based compensation7,1265,657Impairment loss on long-lived asset363619Noncash lease expense966963Changes in operating assets and liabilities:(37,234)(20,696)Inventory33,815(255)Prepaid expenses, net supplier advances, and other assets5,215(4,433)Accounts payable, accrued expenses, and other liabilities17,361(6,034)Net cash provided by (used in) operating activities70,003(18,181)Cash flows from investing activities70,003(18,181)Cash point of property and equipment5-Net cash used in investing activities(528)(907)Cash point financing activities:-22,000Repayments of borrowings on credit facility-22,000Repayments of borrowings on credit facility-22,000Cash received (paid) on notes payable(18)(22)Net cash provided by (used in) financing activities5,89712,153Effects of exchange rate changes on cash and cash equivalents5,89712,153Effects of exchange rate changes on cash and cash equivalents75,584(7,479)Cash and cash equivalents75,584(7,479)Cash and cash equivalents212(544)	(Gain)/loss on disposal of equipment		19		
Stock-based compensation7,1265,657Impairment loss on long-lived asset363619Noncash lease expense966963Changes in operating assets and liabilities:Accounts receivable(37,234)(20,696)Inventory33,815(255)Prepaid expenses, net supplier advances, and other assets5,215(4,433)Accounts payable, accrued expenses, and other liabilities17,361(6,034)Net cash provided by (used in) operating activities70,003(18,181)Cash flows from investing activities70,003(18,181)Cash paid for property and equipment5-Net cash used in investing activities(528)(907)Proceeds from sale of property and equipment5-Proceeds from exercise of stock awards5,9152,675Borrowings on credit facility-(22,000Repayments of borrowings on credit facility-(12,500)Cash received (paid) on notes payable(18)(22)Net cash provided by (used in) financing activities5,89712,153Effects of exchange rate changes on cash and cash equivalents212(544)Net increase/(decrease) in cash and cash equivalents75,584(7,479)Cash and cash equivalents75,584(7,479)Cash and cash equivalents75,584(7,479)	Bad debt expense		255		348
Impairment loss on long-lived asset363619Noncash lease expense966963Changes in operating assets and liabilities:Accounts receivable(37,234)(20,696)Inventory33,815(255)Prepaid expenses, net supplier advances, and other assets5,215(4,433)Accounts payable, accrued expenses, and other liabilities17,361(6,034)Net cash provided by (used in) operating activities70,003(18,181)Cash flows from investing activities:70(18,192)Cash paid for property and equipment5Net cash used in investing activities(528)(907)Proceeds from sale of property and equipment5Net cash used in investing activities(528)(907)Cash flows from financing activities5,9152,675Borrowings on credit facility22,000Repayments of borrowings on credit facility22,000Cash received (paid) on notes payable(18)(222)Net cash provided by (used in) financing activities5,89712,153Effects of exchange rate changes on cash and cash equivalents212(544)Net increase/(decrease) in cash and cash equivalents75,584(7,479)Cash and cash equivalents at beginning of the period19,62928,690	Unrealized (gain)/loss on derivative instruments		1,758		(6,416)
Noncash lease expense966963Changes in operating assets and liabilities:Accounts receivable(37,234)(20,696)Inventory33,815(255)Prepaid expenses, net supplier advances, and other assets5,215(4,433)Accounts payable, accrued expenses, and other liabilities17,361(6,034)Not cash provided by (used in) operating activities70,003(18,181)Cash flows from investing activities:Cash paid for property and equipment5Proceeds from sale of property and equipment(528)(907)Proceeds from sercise of stock awards5,9152,675Borrowings on credit facility22,000Repayments of borrowings on credit facility(12,500)Cash received (paid) on notes payable(18)(22)Net cash provided by (used in financing activities5,89712,153Effects of exchange rate changes on cash and cash equivalents75,584(7,479)Cash and cash equivalents75,584(7,479)Cash and cash equivalents at beginning of the period19,62928,690	Stock-based compensation		7,126		5,657
Changes in operating assets and liabilities:Accounts receivable(37,234)(20,696)Inventory33,815(255)Prepaid expenses, net supplier advances, and other assets5,215(4,433)Accounts payable, accrued expenses, and other liabilities17,361(6,034)Net cash provided by (used in) operating activities70,003(118,181)Cash flows from investing activities:70,003(118,181)Cash paid for property and equipment(533)(907)Proceeds from sale of property and equipment5Net cash used in investing activities(528)(907)Proceeds from sale of property and equipment5Net cash used in investing activities(528)(907)Proceeds from sale of property and equipment5Net cash used in investing activities(528)(907)Cash flows from financing activities5,9152,675Borrowings on credit facility22,000Repayments of borrowings on credit facility(12,500)Cash provided by (used in) financing activities5,89712,153Effects of exchange rate changes on cash and cash equivalents212(544)Net increase/(dcrease) in cash and cash equivalents75,584(7,479)Cash and cash equivalents75,584(7,479)Cash and cash equivalents75,584(7,479)Cash and cash equivalents at beginning of the period19,62928,690	Impairment loss on long-lived asset		363		619
Accounts receivable(37,234)(20,696)Inventory33,815(255)Prepaid expenses, net supplier advances, and other assets5,215(4,433)Accounts payable, accrued expenses, and other liabilities17,361(6,034)Net cash provided by (used in) operating activities70,003(18,181)Cash flows from investing activities:70,003(18,181)Cash paid for property and equipment5Net cash used in investing activities(528)(907)Proceeds from sale of property and equipment5Net cash used in investing activities(528)(907)Cash flows from financing activities(528)(907)Cash flows from financing activities5,9152,675Borrowings on credit facility22,000Repayments of borrowings on credit facility22,000Cash received (paid) on notes payable(18)(22)Net cash provided by (used in) financing activities5,89712,153Effects of exchange rate changes on cash and cash equivalents212(544)Net increase/(decrease) in cash and cash equivalents75,584(7,479)Cash and cash equivalents75,584(7,479)Cash and cash equivalents at beginning of the period19,62928,690	Noncash lease expense		966		963
Inventory33,815(255)Prepaid expenses, net supplier advances, and other assets5,215(4,433)Accounts payable, accrued expenses, and other liabilities17,361(6,034)Net cash provided by (used in) operating activities70,003(18,181)Cash flows from investing activities:70,003(18,181)Cash paid for property and equipment(533)(907)Proceeds from sale of property and equipment5Net cash used in investing activities(528)(907)Cash flows from financing activities:(528)(907)Proceeds from sale of stock awards5,9152,675Borrowings on credit facility22,000Repayments of borrowings on credit facility22,000Cash received (paid) on notes payable(18)(22)Net cash provided by (used in) financing activities5,89712,153Effects of exchange rate changes on cash and cash equivalents75,584(7,479)Cash and cash equivalents75,584(7,479)Cash and cash equivalents at beginning of the period19,62928,690	Changes in operating assets and liabilities:				
Prepaid expenses, net supplier advances, and other assets5,215(4,43)Accounts payable, accrued expenses, and other liabilities17,361(6,034)Net cash provided by (used in) operating activities70,003(18,181)Cash flows from investing activities:70,003(097)Cash paid for property and equipment5Net cash used in investing activities:(533)(907)Proceeds from sale of property and equipment5Net cash used in investing activities(528)(907)Cash flows from financing activities:22,000Proceeds from exercise of stock awards5,9152,675Borrowings on credit facility22,000Repayments of borrowings on credit facility22,000Cash received (paid) on notes payable(18)(22)Net cash provided by (used in) financing activities5,89712,153Effects of exchange rate changes on cash and cash equivalents212(544)Net increase/(decrease) in cash and cash equivalents75,584(7,479)Cash and cash equivalents at beginning of the period19,62928,690	Accounts receivable		(37,234)		(20,696)
Accounts payable, accrued expenses, and other liabilities17,361(6,034)Net cash provided by (used in) operating activities70,003(18,181)Cash flows from investing activities:70,003(18,181)Cash paid for property and equipment(533)(907)907)Proceeds from sale of property and equipment5——Net cash used in investing activities(528)(907)907)Cash flows from financing activities:(528)(907)Proceeds from exercise of stock awards5,9152,675Borrowings on credit facility—22,000Repayments of borrowings on credit facility—(12,500)Cash received (paid) on notes payable(18)(22)Net cash provided by (used in) financing activities5,89712,153Effects of exchange rate changes on cash and cash equivalents212(544)Net increase/(decrease) in cash and cash equivalents75,584(7,479)Cash and cash equivalents19,62928,690	Inventory		33,815		(255)
Net cash provided by (used in) operating activities70,003(18,181)Cash flows from investing activities:(533)(907)Cash paid for property and equipment5Proceeds from sale of property and equipment5Net cash used in investing activities(528)(907)Cash flows from financing activities:(528)(907)Proceeds from exercise of stock awards5,9152,675Borrowings on credit facility22,000Repayments of borrowings on credit facility(12,500)Cash received (paid) on notes payable(18)(22)Net cash provided by (used in) financing activities5,89712,153Effects of exchange rate changes on cash and cash equivalents212(544)Net increase/(decrease) in cash and cash equivalents75,584(7,479)Cash and cash equivalents at beginning of the period19,62928,690	Prepaid expenses, net supplier advances, and other assets		5,215		(4,433)
Cash flows from investing activities:(533)(907)Cash paid for property and equipment(533)(907)Proceeds from sale of property and equipment5Net cash used in investing activities(528)(907)Cash flows from financing activities:Proceeds from exercise of stock awards5,9152,675Borrowings on credit facility22,000Repayments of borrowings on credit facility(12,500)Cash received (paid) on notes payable(18)(22)Net cash provided by (used in) financing activities5,89712,153Effects of exchange rate changes on cash and cash equivalents75,584(7,479)Cash and cash equivalents at beginning of the period19,62928,690	Accounts payable, accrued expenses, and other liabilities		17,361		(6,034)
Cash paid for property and equipment(533)(907)Proceeds from sale of property and equipment5-Net cash used in investing activities(528)(907)Cash flows from financing activities:(528)(907)Proceeds from exercise of stock awards5,9152,675Borrowings on credit facility-22,000Repayments of borrowings on credit facility-(12,500)Cash received (paid) on notes payable(18)(22)Net cash provided by (used in) financing activities5,89712,153Effects of exchange rate changes on cash and cash equivalents212(544)Net increase/(decrease) in cash and cash equivalents75,584(7,479)Cash equivalents at beginning of the period19,62928,690	Net cash provided by (used in) operating activities		70,003		(18,181)
Proceeds from sale of property and equipment5Net cash used in investing activities(528)Cash flows from financing activities:Proceeds from exercise of stock awards5,915Borrowings on credit facility—Repayments of borrowings on credit facility—Cash received (paid) on notes payable(18)Cash provided by (used in) financing activities5,897Effects of exchange rate changes on cash and cash equivalents212Net increase/(decrease) in cash and cash equivalents75,584Cash and cash equivalents at beginning of the period19,62928,690	Cash flows from investing activities:				
Net cash used in investing activities(528)(907)Cash flows from financing activities:Proceeds from exercise of stock awards5,9152,675Borrowings on credit facility22,000Repayments of borrowings on credit facility(12,500)Cash received (paid) on notes payable(18)(22)Net cash provided by (used in) financing activities5,89712,153Effects of exchange rate changes on cash and cash equivalents212(544)Net increase/(decrease) in cash and cash equivalents75,584(7,479)Cash and cash equivalents at beginning of the period19,62928,690	Cash paid for property and equipment		(533)		(907)
Cash flows from financing activities:Proceeds from exercise of stock awards5,9152,675Borrowings on credit facility—22,000Repayments of borrowings on credit facility—(12,500)Cash received (paid) on notes payable(18)(22)Net cash provided by (used in) financing activities5,89712,153Effects of exchange rate changes on cash and cash equivalents212(544)Net increase/(decrease) in cash and cash equivalents75,584(7,479)Cash and cash equivalents at beginning of the period19,62928,690	Proceeds from sale of property and equipment		5		—
Proceeds from exercise of stock awards5,9152,675Borrowings on credit facility—22,000Repayments of borrowings on credit facility—(12,500)Cash received (paid) on notes payable(18)(22)Net cash provided by (used in) financing activities5,89712,153Effects of exchange rate changes on cash and cash equivalents212(544)Net increase/(decrease) in cash and cash equivalents75,584(7,479)Cash and cash equivalents at beginning of the period19,62928,690	Net cash used in investing activities		(528)		(907)
Borrowings on credit facility-22,000Repayments of borrowings on credit facility-(12,500)Cash received (paid) on notes payable(18)(22)Net cash provided by (used in) financing activities5,89712,153Effects of exchange rate changes on cash and cash equivalents212(544)Net increase/(decrease) in cash and cash equivalents75,584(7,479)Cash and cash equivalents at beginning of the period19,62928,690	Cash flows from financing activities:				
Repayments of borrowings on credit facility—(12,500)Cash received (paid) on notes payable(18)(22)Net cash provided by (used in) financing activities5,89712,153Effects of exchange rate changes on cash and cash equivalents212(544)Net increase/(decrease) in cash and cash equivalents75,584(7,479)Cash and cash equivalents at beginning of the period19,62928,690	Proceeds from exercise of stock awards		5,915		2,675
Cash received (paid) on notes payable(18)(22)Net cash provided by (used in) financing activities5,89712,153Effects of exchange rate changes on cash and cash equivalents212(544)Net increase/(decrease) in cash and cash equivalents75,584(7,479)Cash and cash equivalents at beginning of the period19,62928,690	Borrowings on credit facility				22,000
Net cash provided by (used in) financing activities5,89712,153Effects of exchange rate changes on cash and cash equivalents212(544)Net increase/(decrease) in cash and cash equivalents75,584(7,479)Cash and cash equivalents at beginning of the period19,62928,690	Repayments of borrowings on credit facility				(12,500)
Effects of exchange rate changes on cash and cash equivalents212(544)Net increase/(decrease) in cash and cash equivalents75,584(7,479)Cash and cash equivalents at beginning of the period19,62928,690	Cash received (paid) on notes payable		(18)		(22)
Net increase/(decrease) in cash and cash equivalents75,584(7,479)Cash and cash equivalents at beginning of the period19,62928,690	Net cash provided by (used in) financing activities		5,897		12,153
Cash and cash equivalents at beginning of the period 19,629 28,690	Effects of exchange rate changes on cash and cash equivalents		212		(544)
Cash and cash equivalents at beginning of the period 19,629 28,690	Net increase/(decrease) in cash and cash equivalents		75,584		(7,479)
Cash, cash equivalents and restricted cash at end of the period (1) \$95,213 \$21,211	Cash and cash equivalents at beginning of the period		19,629		28,690
	Cash, cash equivalents and restricted cash at end of the period (1)	\$	95,213	\$	21,211

<sup>1</sup>Includes \$328 and \$0 of restricted cash as of September 30, 2023 and 2022, respectively, that were included in other current assets.

## RECONCILIATION FROM GAAP NET INCOME TO NON-GAAP ADJUSTED EBITDA

	Three Months Ended September 30,			Nine Months Ended September 30,			
		2023		2022	2023		2022
(in thousands)							
Net income	\$	15,164	\$	7,258 \$	39,856	\$	10,624
Depreciation and amortization		163		497	503		1,442
Interest income		(824)		(20)	(1,105)		(30)
Interest expense		1		130	31		213
Income tax expense		4,011		1,836	10,101		3,011
EBITDA		18,515		9,701	49,386		15,260
Stock-based compensation (a)		2,862		1,457	7,126		5,657
Unrealized (gain)/loss on derivative instruments (b)		3,959		(952)	1,758		(6,416)
Foreign currency (gain)/loss (b)		1,211		364	430		508
Secondary Offering Costs (c)		_		_	856		_
Other Adjustments (d)		329		1,240	329		1,240
Adjusted EBITDA	\$	26,876	\$	11,810 \$	59,885	\$	16,249

(a) Non-cash charges related to stock-based compensation, which vary from period to period depending on volume and vesting timing of awards. We adjusted for these charges to facilitate comparison from period to period.

(b) Unrealized gains or losses on derivative instruments and foreign currency gains or losses are not considered in our evaluation of our ongoing performance.

(c) Reflects other non-recurring expenses related to costs associated with the secondary offering in which Verlinvest Beverages SA sold shares of the Company in an underwritten public offering, which closed on May 26, 2023. The Company did not receive any proceeds from the sale of the shares.

(d) Reflects other charges primarily related to the impairment loss related to assets held for sale in both periods and other non-recurring expenses.

## SUPPLEMENTAL INFORMATION

	NET SALES									
	Three Months Ended September 30,						Nine Months Ended September 30,			
(in thousands)	2	2023		2022		2022		2023		2022
Americas segment										
Vita Coco Coconut Water	\$	89,683	\$	82,643	\$	253,825	\$	217,934		
Private Label		28,257		24,786		77,366		68,413		
Other		2,706		1,367		7,490		7,553		
Subtotal		120,646		108,796		338,681		293,900		
International segment										
Vita Coco Coconut Water		11,350		10,637		33,628		30,110		
Private Label		5,421		3,810		13,140		9,521		
Other		647		800		2,019		2,265		
Subtotal		17,418		15,247	-	48,787		41,896		
Total net sales	\$	138,064	\$	124,043	\$	387,468	\$	335,796		

	<b>COST OF GOODS SOLD &amp; GROSS PROFIT</b>							
		Three Months En	Nine Months End	ine Months Ended September 30,				
(in thousands)		2023		2022		2023		2022
Cost of goods sold								
Americas segment	\$	70,437	\$	78,516	\$	214,214	\$	220,615
International segment		11,456		12,951		32,328		34,253
Total cost of goods sold	\$	81,893	\$	91,467	\$	246,542	\$	254,868
Gross profit								
Americas segment		50,208		30,279		124,466		73,285
International segment		5,963		2,297		16,460		7,643
Total gross profit	\$	56,171	\$	32,576	\$	140,926	\$	80,928
Gross margin								
Americas segment		41.6 %		27.8 %		36.8 %		24.9 %
International segment		34.2 %		15.1 %		33.7 %		18.2 %
Consolidated		40.7 %		26.3 %		36.4 %		24.1 %

## SUPPLEMENTAL INFORMATION

		VOLUME (CE)						
	Three Months End	led September 30,	Nine Months End	ed September 30,				
(in thousands)	2023	2022	2023	2022				
Americas segment								
Vita Coco Coconut Water	9,234	8,670	26,511	23,269				
Private Label	3,185	2,346	8,454	7,213				
Other	265	200	714	1,092				
Subtotal	12,684	11,216	35,679	31,574				
International segment*								
Vita Coco Coconut Water	1,504	1,581	4,665	4,412				
Private Label	725	492	1,766	1,326				
Other	10	13	46	38				
Subtotal	2,239	2,086	6,477	5,776				
Total volume (CE)	14,923	13,302	42,156	37,350				

Note: A CE is a standard volume measure used by management which is defined as a case of 12 bottles of 330ml liquid beverages or the same liter volume of oil.

\*International Other excludes minor volume that is treated as zero CE